Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for PatientsGlobeNewsWire • 04/19/21
New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple SclerosisGlobeNewsWire • 04/16/21
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple SclerosisGlobeNewsWire • 04/15/21
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021GlobeNewsWire • 04/14/21
Sage (SAGE), Biogen Report Positive Data on Essential Tremor StudyZacks Investment Research • 04/13/21
Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered DrugInvestors Business Daily • 04/12/21
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop OutBenzinga • 04/12/21
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary EndpointBusiness Wire • 04/12/21
Biotech Stocks Could Use A Win — Will The First Quarter Offer That?Investors Business Daily • 04/08/21
Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid ArthritisBenzinga • 04/08/21
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid ArthritisGlobeNewsWire • 04/08/21